ACHILLES THERAPEUTICS PLC Targeting Clonal Neoantigens in Cancer
SAE Media Group Cell and Gene Therapy - 20 June 2023 Sergio Quezada, Chief Scientific Officer, Achilles Therapeutics
Non-Confidential | © Achilles Therapeutics plc 2023 |
Tumour mutations as substrates for immune recognition
TUMOUR | HEALTHY TISSUE |
Tumour | Self antigens |
Tumour associated antigens
(NY-ESO, MAGE, etc)
The ideal tumour target should show the following characteristics:
- Recognised as foreign by the immune system
- Present ONLY on tumour cells (not in healthy tissue)
- Present in ALL tumour cells
Non-Confidential | © Achilles Therapeutics plc 2023 | 1 |
Tumour mutations as substrates for immune recognition (90's)
T. Wölfel Thierry Boon Hans Schreiber
Non-Confidential | © Achilles Therapeutics plc 2023 |
Neo-antigenic burden correlates with immune activation at the tumour site
Cell, 2015
Immune
Non-Confidential | © Achilles Therapeutics plc 2023 |
But… are all neoantigens the same?
Non-Confidential | © Achilles Therapeutics plc 2023 | 4 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Achilles Therapeutics plc published this content on 22 June 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 June 2023 21:11:09 UTC.
